vs

Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.

Strata Critical Medical, Inc. is the larger business by last-quarter revenue ($22.7M vs $20.2M, roughly 1.1× La Rosa Holdings Corp.). On growth, Strata Critical Medical, Inc. posted the faster year-over-year revenue change (361.2% vs 3.2%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs -33.6%).

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.

LRHC vs SRTA — Head-to-Head

Bigger by revenue
SRTA
SRTA
1.1× larger
SRTA
$22.7M
$20.2M
LRHC
Growing faster (revenue YoY)
SRTA
SRTA
+358.0% gap
SRTA
361.2%
3.2%
LRHC
Faster 2-yr revenue CAGR
LRHC
LRHC
Annualised
LRHC
72.5%
-33.6%
SRTA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LRHC
LRHC
SRTA
SRTA
Revenue
$20.2M
$22.7M
Net Profit
$-5.5M
Gross Margin
8.4%
-0.9%
Operating Margin
-24.7%
-18.4%
Net Margin
-27.4%
Revenue YoY
3.2%
361.2%
Net Profit YoY
-125.7%
EPS (diluted)
$-5.44
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LRHC
LRHC
SRTA
SRTA
Q4 25
$22.7M
Q3 25
$20.2M
$49.3M
Q2 25
$23.2M
$70.8M
Q1 25
$17.5M
$54.3M
Q4 24
$17.7M
$-8.7M
Q3 24
$19.6M
$36.1M
Q2 24
$19.1M
$67.9M
Q1 24
$13.1M
$51.5M
Net Profit
LRHC
LRHC
SRTA
SRTA
Q4 25
Q3 25
$-5.5M
$57.4M
Q2 25
$78.4M
$-3.7M
Q1 25
$-95.7M
$-3.5M
Q4 24
$-5.1M
Q3 24
$-2.5M
$-2.0M
Q2 24
$-2.3M
$-11.3M
Q1 24
$-4.6M
$-4.2M
Gross Margin
LRHC
LRHC
SRTA
SRTA
Q4 25
-0.9%
Q3 25
8.4%
23.6%
Q2 25
8.0%
25.1%
Q1 25
8.8%
22.1%
Q4 24
8.9%
Q3 24
8.3%
20.8%
Q2 24
8.3%
24.1%
Q1 24
8.9%
19.7%
Operating Margin
LRHC
LRHC
SRTA
SRTA
Q4 25
-18.4%
Q3 25
-24.7%
-11.4%
Q2 25
-10.6%
-7.0%
Q1 25
-26.7%
-14.0%
Q4 24
-17.1%
Q3 24
-8.9%
-19.7%
Q2 24
-9.7%
-17.9%
Q1 24
-35.0%
-19.2%
Net Margin
LRHC
LRHC
SRTA
SRTA
Q4 25
Q3 25
-27.4%
116.5%
Q2 25
337.8%
-5.3%
Q1 25
-546.5%
-6.4%
Q4 24
-28.7%
Q3 24
-12.5%
-5.4%
Q2 24
-12.2%
-16.7%
Q1 24
-35.1%
-8.2%
EPS (diluted)
LRHC
LRHC
SRTA
SRTA
Q4 25
$-0.11
Q3 25
$-5.44
$0.70
Q2 25
$15.25
$-0.05
Q1 25
$-5.86
$-0.04
Q4 24
$28.54
$-0.11
Q3 24
$-16.49
$-0.03
Q2 24
$-12.49
$-0.15
Q1 24
$-0.35
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LRHC
LRHC
SRTA
SRTA
Cash + ST InvestmentsLiquidity on hand
$4.0M
$31.0M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$1.6M
$279.1M
Total Assets
$21.7M
$325.5M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LRHC
LRHC
SRTA
SRTA
Q4 25
$31.0M
Q3 25
$4.0M
$22.8M
Q2 25
$5.1M
$58.8M
Q1 25
$2.9M
$34.8M
Q4 24
$1.4M
$18.4M
Q3 24
$1.8M
$20.0M
Q2 24
$1.6M
$26.3M
Q1 24
$1.1M
$36.8M
Total Debt
LRHC
LRHC
SRTA
SRTA
Q4 25
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$649.2K
Q2 24
$650.8K
Q1 24
$652.4K
Stockholders' Equity
LRHC
LRHC
SRTA
SRTA
Q4 25
$279.1M
Q3 25
$1.6M
$283.0M
Q2 25
$3.4M
$223.1M
Q1 25
$-87.5M
$219.7M
Q4 24
$2.6M
$221.9M
Q3 24
$5.0M
$233.5M
Q2 24
$4.7M
$229.4M
Q1 24
$5.6M
$236.6M
Total Assets
LRHC
LRHC
SRTA
SRTA
Q4 25
$325.5M
Q3 25
$21.7M
$335.1M
Q2 25
$22.9M
$257.9M
Q1 25
$21.0M
$250.6M
Q4 24
$19.4M
$256.7M
Q3 24
$19.7M
$282.9M
Q2 24
$18.7M
$280.3M
Q1 24
$16.3M
$282.8M
Debt / Equity
LRHC
LRHC
SRTA
SRTA
Q4 25
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LRHC
LRHC
SRTA
SRTA
Operating Cash FlowLast quarter
$-1.3M
$-8.3M
Free Cash FlowOCF − Capex
$-10.2M
FCF MarginFCF / Revenue
-44.7%
Capex IntensityCapex / Revenue
8.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-58.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LRHC
LRHC
SRTA
SRTA
Q4 25
$-8.3M
Q3 25
$-1.3M
$-37.3M
Q2 25
$-1.4M
$-3.1M
Q1 25
$-3.5M
$-246.0K
Q4 24
$-1.1M
$-1.8M
Q3 24
$-591.6K
$6.4M
Q2 24
$-803.1K
$8.4M
Q1 24
$-538.3K
$-15.6M
Free Cash Flow
LRHC
LRHC
SRTA
SRTA
Q4 25
$-10.2M
Q3 25
$-40.1M
Q2 25
$-5.4M
Q1 25
$-2.9M
Q4 24
$-6.3M
Q3 24
$-3.0M
Q2 24
$-7.7M
Q1 24
$-16.4M
FCF Margin
LRHC
LRHC
SRTA
SRTA
Q4 25
-44.7%
Q3 25
-81.4%
Q2 25
-7.6%
Q1 25
-5.3%
Q4 24
72.7%
Q3 24
-8.2%
Q2 24
-11.4%
Q1 24
-31.8%
Capex Intensity
LRHC
LRHC
SRTA
SRTA
Q4 25
8.1%
Q3 25
5.7%
Q2 25
3.2%
Q1 25
4.8%
Q4 24
-52.6%
Q3 24
25.8%
Q2 24
23.8%
Q1 24
1.6%
Cash Conversion
LRHC
LRHC
SRTA
SRTA
Q4 25
Q3 25
-0.65×
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

SRTA
SRTA

Other Clinical$11.4M50%
Transplant Clinical$9.0M39%
Other$2.4M11%

Related Comparisons